Treatment issues surrounding hepatitis C in renal transplantation: a review

Area of Science:

• Hepatology
• Transplant Medicine
• Virology

Background:

• Hepatitis C virus (HCV) infection is common in solid organ transplant candidates and recipients.
• HCV negatively impacts long-term survival and graft function in renal transplant patients.
• Outcomes of HCV in heart and lung transplant recipients require further investigation.

Purpose of the Study:

• To review the efficacy of amantadine, ribavirin, and interferon-based therapies for chronic hepatitis C in renal transplant recipients.
• To highlight the challenges in managing HCV in solid organ transplant recipients due to limited safe antiviral options.
• To emphasize the need for pre-transplant HCV treatment and future large-scale trials.

Main Methods:

• Literature review of peer-reviewed studies.
• Focus on treatments including amantadine, ribavirin, standard interferon, and pegylated interferon.
• Analysis of treatment efficacy in renal transplant recipients with chronic hepatitis C.

Main Results:

• Pre-transplant interferon-based therapy for HCV may enhance post-transplant outcomes.
• Post-transplant interferon therapy is linked to a higher risk of graft rejection.
• Limited data exists on optimal HCV management in solid organ transplant recipients.

Conclusions:

• HCV management in solid organ transplant recipients is challenging due to treatment limitations.
• Pre-transplant treatment strategies for HCV are crucial for improving transplant outcomes.
• Large-scale, multi-center randomized controlled trials are essential to establish optimal HCV treatment protocols for this population.